Combs Andrew 4
4 · Prelude Therapeutics Inc · Filed Apr 4, 2022
Insider Transaction Report
Form 4
Combs Andrew
Chief Chemistry Officer
Transactions
- Exercise/Conversion
Employee Stock Option (right to buy)
2022-04-01−36,062→ 50,397 totalExercise: $1.89Exp: 2030-03-26→ Common Stock (36,062 underlying) - Exercise/Conversion
Common Stock
2022-03-31$1.89/sh+36,062$68,157→ 304,442 total
Footnotes (2)
- [F1]Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.
- [F2]The stock option vested as to 25% of the total shares on March 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.